2 results
Approved WMOWill not start
Pertuzumab is an investigational agent being studied for the treatment of HER2-positive gastric cancer. This study intends to provide a dose of pertuzumab to find an acceptable minimum pertuzumabconcentratie pertuzumab effective when administered in…
Approved WMOCompleted
To compare progression-free survival (PFS) between the two treatment arms based on assessments by an independent review facility (IRF).